Adenosine Receptor Biased Agonism to Treat Ischaemic Heart Disease

腺苷受体偏向激动治疗缺血性心脏病

• 批准号: nhmrc : 1084487
• 负责人: A/Pr Bing Wang
• 金额: $ 45.49万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/adenosine-receptor-biased-heart-disease/519010
• 关键词: Adenosine; Receptor; Biased; Agonism; Treat

Adenosine A1 receptor (A1R) activation confers powerful protection to heart cells, however clinical application remains suboptimal due to adverse effects such as a slowing in heart rate and decrease in blood pressure. Importantly a new class of compounds, A1R biased agonists, can mediate potent cardioprotection in the absence of adverse effects. This proposal will establish the molecular mechanisms involved and the scope to develop A1R biased agonists as a novel approach to treat heart disease.

腺苷A1受体（A1R）的激活对心脏细胞具有强大的保护作用，但由于心率减慢和血压降低等不良反应，临床应用仍不理想。重要的是，一类新的化合物，A1R偏向激动剂，可以介导有效的心脏保护，而没有不良反应。这一建议将建立所涉及的分子机制和范围，以开发A1受体偏性激动剂作为一种新的方法来治疗心脏病。